Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Immunocore

6 Disclosed Funding Rounds $668,834,313

0 Participating Investments


Pharmaceutical, Biotechnology, Medical

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies.

Abingdon, Oxfordshire, United Kingdom, Europe (GB)

Organizations in Abingdon in Pharmaceutical,
Organizations in Abingdon in Biotechnology,
Organizations in Abingdon in Medical,
Organizations in Oxfordshire in Pharmaceutical,
Organizations in Oxfordshire in Biotechnology,
Organizations in Oxfordshire in Medical,
Organizations in United Kingdom in Pharmaceutical,
Organizations in United Kingdom in Biotechnology,
Organizations in United Kingdom in Medical,
Organizations in Europe in Pharmaceutical,
Organizations in Europe in Biotechnology,
Organizations in Europe in Medical

Investors in Abingdon in Pharmaceutical,
Investors in Abingdon in Biotechnology,
Investors in Abingdon in Medical,
Investors in Oxfordshire in Pharmaceutical,
Investors in Oxfordshire in Biotechnology,
Investors in Oxfordshire in Medical,
Investors in United Kingdom in Pharmaceutical,
Investors in United Kingdom in Biotechnology,
Investors in United Kingdom in Medical,
Investors in Europe in Pharmaceutical,
Investors in Europe in Biotechnology,
Investors in Europe in Medical

Founded date 01, 2008

Founders Bent Jakobsen

Operating Status Active

Funding Stage IPO

Last Funding Type Debt Financing

Company Type For Profit


Facebook Link

Twitter Link

LinkedIN Link

Wikipedia Link

Immunocore is a focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.

Date Round Raised Lead
January, 11, 2021 Debt Financing $100,000,000 Oxford Finance LLC
January, 11, 2021 Series C $75,000,000 BlackRock
March, 02, 2020 Series B $130,000,000 General Atlantic
September, 18, 2017 Series B $40,000,000 Bill & Melinda Gates Foundation
July, 16, 2015 Series A $320,000,000 Woodford Investment Management
November, 05, 2012 Grant $3,834,312 Biomedical Catalyst Fund

Immunocore Investors (16)

Investor Lead? Round Participating Raise Date Partners
BlackRock Yes Series C $75,000,000 January, 11, 2021 -------
Oxford Finance LLC Yes Debt Financing $100,000,000 January, 11, 2021 -------
General Atlantic Yes Series B $130,000,000 March, 02, 2020 -------
Terra Magnum Capital Partners ("TMCP") No Series B $130,000,000 March, 02, 2020 -------
WuXi AppTec No Series B $130,000,000 March, 02, 2020 -------
RTW Investments LLC No Series B $130,000,000 March, 02, 2020 -------
Rock Springs Capital No Series B $130,000,000 March, 02, 2020 -------
JDRF T1D Fund No Series B $130,000,000 March, 02, 2020 -------
Eli Lilly No Series B $130,000,000 March, 02, 2020 -------
CCB International No Series B $130,000,000 March, 02, 2020 -------
Bill & Melinda Gates Foundation No Series B $130,000,000 March, 02, 2020 -------
Bill & Melinda Gates Foundation Yes Series B $40,000,000 September, 18, 2017 -------
RTW Investments LLC No Series A $320,000,000 July, 16, 2015 -------
Woodford Investment Management Yes Series A $320,000,000 July, 16, 2015 -------
Eli Lilly No Series A $320,000,000 July, 16, 2015 -------
Biomedical Catalyst Fund Yes Grant $3,834,312 November, 05, 2012 -------